Eli Lilly developed Zepbound and trades on the New York Stock Exchange under the ticker LLY.
Eli Lilly and Company was founded in 1876 by Colonel Eli Lilly, a pharmaceutical chemist in Indianapolis, Indiana. The company has produced medicines in areas including diabetes, oncology, neuroscience, and immunology.
Zepbound is the brand name for tirzepatide when prescribed for chronic weight management in eligible adults. The same active ingredient is marketed as Mounjaro for type 2 diabetes. Tirzepatide acts on GIP and GLP-1 hormone pathways.
Zepbound is often confused with Wegovy, which contains semaglutide and is made by Novo Nordisk. Both medicines belong to the modern class of prescription weight-management treatments, but they are different products and have different manufacturers.